Search results
Results from the WOW.Com Content Network
Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.
Another GLP-1 drug, Trulicity, which is also used to treat type 2 diabetes, was its third-best-selling drug, but saw its sales fall 31% to $1.25 billion as patients shifted to its newer GLP-1 ...
Science & Tech. Shopping. Sports
The drugs, known as GLP-1s, have brought in $50 billion in revenue for Novo Nordisk year to date alone, but the high prices ($1,349 for Wegovy and $968 for Ozempic) have put them out of reach for ...
Global Partners LP (NYSE: GLP) is an American energy supply company ranked 361 in the 2018 Fortune 500. [3] The company is organized as a master limited partnership, and its operations focus on the importing of petroleum products and marketing them in North America. It wholesales products like crude oil, diesel oil, gasoline, heating oil and ...
[18] [17] In July 2017, Mei's consortium won the bid to acquire GLP and take the company private for S$16 billion ($11.6 billion). [3] More than 96 percent of the company's shareholders voted for GLP to delist from the Singapore Stock Exchange in November 2017; it was officially delisted on January 22, 2018. [19]
Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. As of 2017 it is unclear if it affects a person's risk of death. [ 2 ]
Based on analyst projections of future earnings, the stock is trading at a forward price-to-earnings multiple of just 16, which makes it a fairly compelling value buy for growth investors. The ...